Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
1.
Br Poult Sci ; 62(3): 361-372, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33448227

RESUMO

1. The objective of this study was to characterise circulating Brazilian avian reovirus (ARV) strains by genetic analysis of the σC protein encoded by segment 1 of the viral genome and compare these with those of viral strains used for immunising commercial poultry.2. The analysis detected the presence of ARV genomes by quantitative reverse transcriptase PCR (RT-qPCR) in the enteric samples and the joint tissues (JT) of birds with signs of viral arthritis/tenosynovitis. Nucleotide sequencing used 16 strains (three commercial vaccines, 10 from enteric tissues and three from JT). The results indicated high variability in the amino acid sequences of 13 wild strains, showing between 40% and 75% similarity compared with the vaccine strains (S1133 and 2177).3. The sequences were grouped into three well-defined clusters in a phylogenetic tree, two of these clusters together with previous Brazilian σC ARV sequences, and one cluster (VII) that was novel for Brazilian strains. Antigenic analysis showed that there were amino acids within putative epitopes located on the surface of the receptor-binding region of the σC protein with a high degree of variability.4. The study confirmed the presence of ARV genetic variants circulating in commercial birds in Brazil, and according to the antigenic prediction, the possibility of antigenic variants appears to be high.


Assuntos
Artrite , Orthoreovirus Aviário , Doenças das Aves Domésticas , Tenossinovite , Animais , Artrite/veterinária , Brasil/epidemiologia , Galinhas , Orthoreovirus Aviário/genética , Filogenia , Aves Domésticas , Doenças das Aves Domésticas/epidemiologia , Tenossinovite/veterinária
2.
J Pediatr Endocrinol Metab ; 17 Suppl 3: 457-62, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15134307

RESUMO

The possible impact of IUGR on the intellectual outcome of children born with IUGR gives special relevance to this condition. In order to determine the psychomotor and intellectual development of such children, we analyzed the evolution of 60 children through appropriate tests, along the years, and the possible influence of two factors, the socio-economic status of the family, and whether or not there was catch-up growth. Our results show a negative impact of IUGR on the intellectual outcome of these children, independent of catch-up growth, although those with catch-up growth showed better evolution. The socio-economic status plays a limited role only at older age. Those children followed longitudinally for 1 year did not show any amelioration of their IQ.


Assuntos
Deficiências do Desenvolvimento/diagnóstico , Retardo do Crescimento Fetal/complicações , Retardo do Crescimento Fetal/fisiopatologia , Transtornos Psicomotores/diagnóstico , Adolescente , Atenção , Criança , Pré-Escolar , Deficiências do Desenvolvimento/complicações , Feminino , Crescimento/fisiologia , Humanos , Lactente , Inteligência , Testes de Inteligência/normas , Estudos Longitudinais , Masculino , Agitação Psicomotora/diagnóstico , Transtornos Psicomotores/complicações , Classe Social , Fatores Socioeconômicos , Espanha , Fatores de Tempo
3.
Rev Med Chil ; 126(9): 1093-9, 1998 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-9922513

RESUMO

BACKGROUND: Acute lymphoblastic leukemia has a different evolution in children and adults. Complete remission is achieved in 70-85% of the latter, but only 25 to 35% have a prolonged disease-free survival. AIM: To assess the treatment outcome of adults with acute lymphoblastic leukemia in Chile. PATIENTS AND METHODS: A retrospective review of the medical files of 51 adults with acute lymphoblastic leukemia treated according to the national protocol for antineoplastic drugs, in a public hospital of Santiago. RESULTS: Mean age of patients was 35.9 years old and 53% were younger than 20 years old. Complete remission was achieved in 64%. Early mortality occurred in 22%, mostly due to infections. Treatment failure occurred in 16%. Global survival was 17 months and global survival at 5 years was 24%. Prognostic criteria of the protocol, defined a low risk group that had a complete remission of 100%, no early deaths and 5 year disease-free survival of 53%. The group defined as having high risk had a complete remission of 47%, a 29% early mortality and a 5 years disease-free survival of 6%. CONCLUSIONS: Aiming to improve treatment results in acute lymphoblastic leukemia, efforts should be made to improve the management of febrile neutropenic patients and to intensify chemotherapy.


Assuntos
Antineoplásicos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adulto , Chile , Protocolos Clínicos , Intervalo Livre de Doença , Humanos , Estudos Retrospectivos , Resultado do Tratamento
4.
Rev Med Chil ; 125(4): 433-7, 1997 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-9460284

RESUMO

BACKGROUND: A recent update of FAB classification has included a myeloid leukemia subtype with a minimal degree of differentiation, that has been denominated LMA-MO. AIM: To report the clinical, morphological and immunophenotypic features of patients with LMA-MO. PATIENTS AND METHODS: Eight patients, out of 368, with acute myeloid leukemia that were studied in the Hematology Laboratory of a public hospital in Santiago, were classified as LMA-MO. RESULTS: Blast cell morphology was undifferentiated or of subtype FAB-L2 lymphoblastic leukemia with medium sized blasts, agranular basophilic cytoplasm, reticular nuclear chromatin and a prominent nucleolus. Cytochemical staining was negative for peroxidase and esterases, immunophenotyping showed the expression of one or more myeloid antigens (CD13, CD33) and was negative for lymphoid antigens. Immunocytochemical expression of myeloperoxidase was positive in the three cases where it was performed. Only one patient achieved complete remission and is free of disease after 36 months of follow up. All other patients died without obtaining remission, six shortly after the onset and one 12 months after. CONCLUSIONS: The diagnosis of LMA-MO is essential considering its dismal prognosis.


Assuntos
Leucemia Mieloide/diagnóstico , Doença Aguda , Idoso , Medula Óssea/patologia , Feminino , Humanos , Imunofenotipagem , Lactente , Recém-Nascido , Leucemia Mieloide/sangue , Masculino , Pessoa de Meia-Idade
5.
Artigo em Inglês | MEDLINE | ID: mdl-3465182

RESUMO

The differences existing among some european longitudinal growth studies make it necessary to be cautious in the use of standards constructed on different populations. The improvement of the environmental conditions during the last 20 years is probably the most important cause of the "catch-up" phenomenon of the spanish stature. It is probable that racial characteristics also play a role, even in the same country as can be appreciated on comparing two spanish longitudinal studies based on children originally from different regions. All of which indicates the need to use own standards in those countries which, like ours, have lived through a period of intense changes. Even exploratory studies of regional differences in the same country seem necessary.


Assuntos
Crescimento , Determinação da Idade pelo Esqueleto , Estatura , Peso Corporal , Cefalometria , Europa (Continente) , Feminino , Humanos , Recém-Nascido , Estudos Longitudinais , Masculino , Metacarpo/anatomia & histologia , Dobras Cutâneas , Espanha
6.
Rev Med Chil ; 128(11): 1191-8, 2000 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-11347505

RESUMO

BACKGROUND: The incidence of acute myeloid leukemia is 3 cases per 100,000 inhabitants/year and its five years event free survival is 15 to 20%. Since the incorporation of trans retinoic acid, event free survival of M3 acute myeloid leukemia is 80%. AIM: To report the results of acute myeloid leukemia treatment at the Hospital del Salvador, between 1990 and 1998. PATIENTS AND METHODS: The medical records of 117 patients (66 female, mean age 48.2 years), treated between 1990 and 1998 using PANDA protocol, were retrospectively reviewed. Immunophenotyping was done in 69 patients and cytogenetic studies were done in 65. RESULTS: Sixteen percent of patients had M3 acute myeloid leukemia. The most frequent phenotype was the association of DR, CD34 plus a panmyeloid marker. DR and CD34 were negative in seven of nine patients with M3 acute myeloid leukemia. Cariotype was abnormal in 78% of patients. Complete remission was achieved in 65% of cases with a 13% of failures. Early mortality was 21.3% and decreased to 6.1% in the last three years. Infections and coagulation disorders were the main causes of death. Mean survival was 10.5 months. Five years event free survival was 11%. In M3 acute myeloid leukemia, the figure is 50%. CONCLUSIONS: Treatment results are less effective than protocols that consider more aggressive chemotherapeutic protocols or bone marrow transplantation. The reduction in early mortality is due to a better management of febrile neutropenia.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Promielocítica Aguda/tratamento farmacológico , Adolescente , Adulto , Idoso , Quimioterapia Adjuvante , Citarabina/administração & dosagem , Daunorrubicina/administração & dosagem , Intervalo Livre de Doença , Feminino , Humanos , Idarubicina/uso terapêutico , Imunofenotipagem , Leucemia Promielocítica Aguda/genética , Leucemia Promielocítica Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Mitoxantrona/uso terapêutico , Prognóstico , Estudos Retrospectivos , Resultado do Tratamento
7.
Rev. méd. Chile ; 131(9): 1023-1030, sept. 2003.
Artigo em Espanhol | LILACS | ID: lil-356010

RESUMO

BACKGROUND: Febrile neutropenia is one of the most important problems to face during the treatment of acute leukemia. AIM: To assess the results of a standardized protocol for the treatment of febrile neutropenia and compare it with a period in which treatment was not standardized. PATIENTS AND METHODS: One hundred and eight episodes of febrile neutropenia in 69 patients, treated with a standardized antimicrobial protocol between 1996 and 2001, were analyzed. The protocol consisted in the use of a combination of antimicrobial whose spectrum was broadened progressively according to the isolated microorganisms and the involved foci. These were compared with 83 episodes in 54 patients, treated without standardized protocols between 1990 and 1995. RESULTS: Both groups of patients were comparable. Their ages ranged from 15 to 65 years old. The male/female ratio was 1.3 and the lymphoblastic/myeloid leukemia ratio was 1.4. Sixty one percent of episodes occurred during induction chemotherapy and mean duration of neutropenia was 17 days. A clinically significant focus was identified in 72 per cent of episodes and a microorganism was isolated blood culture in 35 per cent of them. There was a predominance of gram negative organisms. The mortality decreased from 18 to 9 per cent in the period 1996-2000 (p = 0.094). CONCLUSIONS: The use of a standardized antimicrobial protocol reduced the mortality in febrile neutropenia, even when colony stimulating factors and filtered air rooms are unavailable.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Febre/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia Mieloide/tratamento farmacológico , Neutropenia/tratamento farmacológico , Quimioterapia Combinada , Antineoplásicos/efeitos adversos , Chile , Doença Aguda , Estudos Retrospectivos , Febre/induzido quimicamente , Febre/mortalidade , Neutropenia/induzido quimicamente , Neutropenia/mortalidade , Programas Nacionais de Saúde , Risco
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa